Home Metabolism AhR inhibitor - ROS inhibitor - CCR inhibitor - Nrf2 activator Perillaldehyde

research use only

Perillaldehyde AhR inhibitor

Cat.No.S3205

Perillaldehyde (Perilladehyde, Perillal, PAE, PA), the main component of Perilla frutescens (a traditional medicinal antioxidant herb), inhibits BaP-induced AHR activation and ROS production, inhibits BaP/AHR-mediated release of the CCL2 chemokine, and activats the NRF2/HO1 antioxidant pathway.
Perillaldehyde AhR inhibitor Chemical Structure

Chemical Structure

Molecular Weight: 150.22

Jump to Mechanism of Action Solubility Chemical Information, Storage & Stability Specificity

Quality Control

Chemical Information, Storage & Stability

Molecular Weight 150.22 Formula

C10H14O

 Storage (From the date of receipt) 2 years -20°C liquid
CAS No. 18031-40-8 -- Storage of Stock Solutions

Synonyms Perilladehyde, Perillal, PAE, PA Smiles CC(=C)C1CCC(=CC1)C=O

Solubility

In vitro
Batch:

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Targets/IC50/Ki
AhR [1]
ROS [1]
CCL2 chemokine [1]
NRF2/HO1 [1]
NRF2/HO1 [1]
References

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT06077526 Not yet recruiting
Chronic Pain
Bridgewater College
 January 13 2026 Not Applicable
NCT06018844 Not yet recruiting
Type 1 Diabetes
Children''s Mercy Hospital Kansas City|University of Kansas|Nemours Children''s Clinic
 April 2025 --
NCT06365723 Not yet recruiting
PreDiabetes
University of Minnesota
 January 15 2025 Not Applicable
NCT05990062 Not yet recruiting
Amputation Surgical
VA Office of Research and Development|Stumpworx LLC
 October 1 2024 Not Applicable
NCT04600713 Not yet recruiting
Atrial Fibrillation Paroxysmal
Vastra Gotaland Region
 October 2024 Not Applicable

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.